Oric(ORIC) - 2024 Q4 - Annual Results

Financial Position - ORIC Pharmaceuticals reported cash and investments of $256 million as of December 31, 2024, expected to fund operations into late 2026[12]. - The company secured$125 million in financing during 2024, extending its cash runway into late 2026[2]. - The total stockholders' equity increased to $243.1 million as of December 31, 2024, up from$224.1 million in 2023[16]. Research and Development Expenses - Research and development (R&D) expenses for Q4 2024 were $32.0 million, up from$24.5 million in Q4 2023, representing a 29% increase[12]. - For the full year 2024, R&D expenses totaled $114.1 million, compared to$85.2 million in 2023, marking a 34% increase[12]. General and Administrative Expenses - General and administrative (G&A) expenses for Q4 2024 were $7.6 million, compared to$6.9 million in Q4 2023, an increase of 10%[12]. Net Loss - The net loss for Q4 2024 was $36.3 million, compared to a net loss of$28.3 million in Q4 2023, reflecting a 28% increase in losses[18]. Clinical Programs and Trials - ORIC anticipates seven data readouts across ORIC-114 and ORIC-944 clinical programs over the next 18 months, with potential registrational trials starting in 2H25 and early 2026[1]. - ORIC-944 is being evaluated in combination with apalutamide and darolutamide in ongoing Phase 1b trials for metastatic castration-resistant prostate cancer (mCRPC)[7]. - ORIC-114 is in clinical collaboration with Johnson & Johnson for the treatment of non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutations[3].